Skip to main content

Tasimelteon Disease Interactions

There are 4 disease interactions with tasimelteon.

Major

Anxiolytics/sedatives/hypnotics (applies to tasimelteon) depression

Major Potential Hazard, Moderate plausibility.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References (14)
  1. (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
  2. (2001) "Product Information. Ambien (zolpidem)." sanofi-aventis
  3. (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
  4. (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
  5. (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
  6. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  7. (2001) "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical
  8. (2002) "Product Information. Xyrem (sodium oxybate)." Orphan Medical
  9. (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
  10. (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
  11. (2010) "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals
  12. (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
  13. (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
  14. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
Major

Anxiolytics/sedatives/hypnotics (applies to tasimelteon) severe renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.

References (5)
  1. (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
  2. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  3. (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
  4. (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
  5. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
Moderate

Anxiolytics/sedatives/hypnotics (applies to tasimelteon) glaucoma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Urinary Retention

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

References (2)
  1. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  2. (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
Moderate

Anxiolytics/sedatives/hypnotics (applies to tasimelteon) liver disease

Moderate Potential Hazard, Moderate plausibility.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

References (13)
  1. (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
  2. (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
  3. (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
  4. (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
  5. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  6. (2001) "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical
  7. (2002) "Product Information. Xyrem (sodium oxybate)." Orphan Medical
  8. (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
  9. (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
  10. (2010) "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals
  11. (2011) "Product Information. Intermezzo (zolpidem)." Purdue Pharma LP
  12. (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
  13. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc

Switch to consumer interaction data

Tasimelteon drug interactions

There are 444 drug interactions with tasimelteon.

Tasimelteon alcohol/food interactions

There is 1 alcohol/food interaction with tasimelteon.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer